New hope for PNH patients failing standard therapy

NCT ID NCT07154745

Recruiting now Disease control Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study is testing a new combination of two drugs, pozelimab and cemdisiran, for people with Paroxysmal Nocturnal Hemoglobinuria (PNH) whose current C5 inhibitor treatment isn't fully controlling the destruction of their red blood cells. The main goal is to see if this combination can better reduce this destruction, measured by a blood test called LDH, over 28 weeks. The study will also track side effects, changes in fatigue and hemoglobin levels, and how long the treatment's effects last.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

AOU Careggi
RECRUITING

Florence, Tuscany, 50134, Italy
Ewha Womans University Mokdong Hospital
RECRUITING

Seoul, 07985, South Korea
Hospital San Pedro de Alcantara
RECRUITING

Cáceres, 10003, Spain
In-Vivo Sp. z o.o.
RECRUITING

Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 85-048, Poland
Seoul National University Hospital
RECRUITING

Seoul, 03080, South Korea

Conditions

Explore the condition pages connected to this study.

PAROXYSMAL NOCTURNAL HEMOGLOBINURIA